Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for negotiation, quelling fears about price caps.
Moderna, Merck, Pfizer, Bristol-Myers Squibb, Eli Lilly and Novo Nordisk were among the gainers.
Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
German pharmaceutical company Bayer plans discontinue the production of active ingredients of crop protection products at its Dormagen site, which are available at lower prices on the global market, resulting in 200 job cuts.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 12, 2025 17:20 ET (21:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.